News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Asklepios BioPharmaceutical, Inc. Enters Into A Patent License Agreement With Pfizer Inc. (PFE)



9/13/2010 11:52:38 AM

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Asklepios BioPharmaceutical, Inc. (AskBio), a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV). HCV infection is the most common chronic blood-borne infection in the United States, with approximately 3.2 million people chronically infected.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES